{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T16:38:42Z","timestamp":1778603922675,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,6,12]],"date-time":"2017-06-12T00:00:00Z","timestamp":1497225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"nature science foundation of Shanxi Province","award":["2013011052-3"],"award-info":[{"award-number":["2013011052-3"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s13760-017-0795-6","type":"journal-article","created":{"date-parts":[[2017,6,12]],"date-time":"2017-06-12T02:42:47Z","timestamp":1497235367000},"page":"695-702","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Effectiveness of low dose of rituximab compared with azathioprine in Chinese patients with neuromyelitis optica: an over 2-year follow-up study"],"prefix":"10.1007","volume":"117","author":[{"given":"Meini","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuntao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiru","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,12]]},"reference":[{"issue":"2","key":"795_CR1","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/WNO.0b013e31825662f1","volume":"32","author":"MJ Morrow","year":"2012","unstructured":"Morrow MJ, Wingerchuk D (2012) Neuromyelitis optica. J Neuroophthalmol 32(2):154\u2013166","journal-title":"J Neuroophthalmol"},{"issue":"9","key":"795_CR2","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","volume":"6","author":"DM Wingerchuk","year":"2007","unstructured":"Wingerchuk DM, Lennon VA, Lucchinetti CF et al (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6(9):805\u2013815","journal-title":"Lancet Neurol"},{"issue":"11","key":"795_CR3","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s00415-009-5171-x","volume":"256","author":"E Bizzoco","year":"2009","unstructured":"Bizzoco E, Lolli F, Repice AM et al (2009) Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J Neurol 256(11):1891\u20131898","journal-title":"J Neurol"},{"issue":"Pt 7","key":"795_CR4","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","volume":"125","author":"CF Lucchinetti","year":"2002","unstructured":"Lucchinetti CF, Mandler RN, Mcgavern D et al (2002) A role for humoral mechanisms in the pathogenesis of Devic\u2019s neuromyelitis optica. Brain 125(Pt 7):1450\u20131461","journal-title":"Brain"},{"issue":"3","key":"795_CR5","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/archneur.63.3.390","volume":"63","author":"SJ Pittock","year":"2006","unstructured":"Pittock SJ, Lennon VA, Krecke K et al (2006) Brain abnormalities in neuromyelitis optica. Arch Neurol 63(3):390\u2013396","journal-title":"Arch Neurol"},{"issue":"18","key":"795_CR6","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1097\/WNR.0b013e32835ab480","volume":"23","author":"S Saadoun","year":"2012","unstructured":"Saadoun S, Bridges LR, Verkman AS et al (2012) Paucity of natural killer and cytotoxic T cells in human neuromyelitis optica lesions. NeuroReport 23(18):1044\u20131047","journal-title":"NeuroReport"},{"issue":"1","key":"795_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","volume":"261","author":"C Trebst","year":"2014","unstructured":"Trebst C, Jarius S, Berthele A et al (2014) Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 261(1):1\u201316","journal-title":"J Neurol"},{"issue":"4","key":"795_CR8","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.msard.2012.06.002","volume":"1","author":"DJ Kimbrough","year":"2012","unstructured":"Kimbrough DJ, Fujihara K, Jacob A et al (2012) Treatment of neuromyelitis optica: review and recommendations. Mult Scler Relat Disord 1(4):180\u2013187","journal-title":"Mult Scler Relat Disord"},{"issue":"6 Suppl 12","key":"795_CR9","first-page":"9","volume":"27","author":"AJ Grillo-Lopez","year":"2000","unstructured":"Grillo-Lopez AJ (2000) Rituximab: an insider\u2019s historical perspective. Semin Oncol 27(6 Suppl 12):9\u201316","journal-title":"Semin Oncol"},{"issue":"Pt 11","key":"795_CR10","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1093\/brain\/awn240","volume":"131","author":"S Jarius","year":"2008","unstructured":"Jarius S, Aboul-Enein F, Waters P et al (2008) Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 131(Pt 11):3072\u20133080","journal-title":"Brain"},{"issue":"15","key":"795_CR11","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","volume":"76","author":"HL Pellkofer","year":"2011","unstructured":"Pellkofer HL, Krumbholz M, Berthele A et al (2011) Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 76(15):1310\u20131315","journal-title":"Neurology"},{"issue":"7","key":"795_CR12","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","volume":"64","author":"BA Cree","year":"2005","unstructured":"Cree BA, Lamb S, Morgan K et al (2005) An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64(7):1270\u20131272","journal-title":"Neurology"},{"issue":"11","key":"795_CR13","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","volume":"65","author":"A Jacob","year":"2008","unstructured":"Jacob A, Weinshenker BG, Violich I et al (2008) Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 65(11):1443\u20131448","journal-title":"Arch Neurol"},{"issue":"11","key":"795_CR14","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","volume":"68","author":"SH Kim","year":"2011","unstructured":"Kim SH, Kim W, Li XF et al (2011) Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2\u00a0years. Arch Neurol 68(11):1412\u20131420","journal-title":"Arch Neurol"},{"issue":"10","key":"795_CR15","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/1352458511404586","volume":"17","author":"GS Bedi","year":"2011","unstructured":"Bedi GS, Brown AD, Delgado SR et al (2011) Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler 17(10):1225\u20131230","journal-title":"Mult Scler"},{"issue":"9","key":"795_CR16","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","volume":"70","author":"SH Kim","year":"2013","unstructured":"Kim SH, Huh SY, Lee SJ et al (2013) A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol 70(9):1110\u20131117","journal-title":"JAMA Neurol"},{"issue":"11","key":"795_CR17","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","volume":"65","author":"A Jacob","year":"2008","unstructured":"Jacob A, Weinshenker BG, Violich I et al (2008) Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 65(11):1443\u20131448","journal-title":"Arch Neurol"},{"issue":"3","key":"795_CR18","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","volume":"71","author":"MA Mealy","year":"2014","unstructured":"Mealy MA, Wingerchuk DM, Palace J et al (2014) Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol 71(3):324\u2013330","journal-title":"JAMA Neurol"},{"issue":"8","key":"795_CR19","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1212\/WNL.0b013e3182a1aac7","volume":"81","author":"CS Yang","year":"2013","unstructured":"Yang CS, Yang L, Li T et al (2013) Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. Neurology 81(8):710\u2013713","journal-title":"Neurology"},{"issue":"6","key":"795_CR20","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1212\/01.wnl.0000444161.12981.ba","volume":"82","author":"HJ Kim","year":"2014","unstructured":"Kim HJ, Kim SH (2014) Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. Neurology 82(6):546\u2013547","journal-title":"Neurology"},{"issue":"7","key":"795_CR21","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.jocn.2015.01.028","volume":"22","author":"W Qiu","year":"2015","unstructured":"Qiu W, Kermode AG, Li R et al (2015) Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica. J Clin Neurosci 22(7):1178\u20131182","journal-title":"J Clin Neurosci"},{"issue":"7","key":"795_CR22","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","volume":"77","author":"C Costanzi","year":"2011","unstructured":"Costanzi C, Matiello M, Lucchinetti CF et al (2011) Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 77(7):659\u2013666","journal-title":"Neurology"},{"issue":"9","key":"795_CR23","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/archneurol.2010.203","volume":"67","author":"DB Bichuetti","year":"2010","unstructured":"Bichuetti DB, Lobato DOE, Oliveira DM et al (2010) Neuromyelitis optica treatment: analysis of 36 patients. Arch Neurol 67(9):1131\u20131136","journal-title":"Arch Neurol"},{"issue":"6","key":"795_CR24","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1468-1331.2009.02928.x","volume":"17","author":"MA Sahraian","year":"2010","unstructured":"Sahraian MA, Moinfar Z, Khorramnia S et al (2010) Relapsing neuromyelitis optica: demographic and clinical features in Iranian patients. Eur J Neurol 17(6):794\u2013799","journal-title":"Eur J Neurol"},{"issue":"2","key":"795_CR25","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85(2):177\u2013189","journal-title":"Neurology"},{"issue":"8","key":"795_CR26","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1177\/1352458507077189","volume":"13","author":"S Watanabe","year":"2007","unstructured":"Watanabe S, Misu T, Miyazawa I et al (2007) Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler 13(8):968\u2013974","journal-title":"Mult Scler"},{"issue":"10","key":"795_CR27","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1007\/s00415-015-7852-y","volume":"262","author":"H Zephir","year":"2015","unstructured":"Zephir H, Bernard-Valnet R, Lebrun C et al (2015) Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. J Neurol 262(10):2329\u20132335","journal-title":"J Neurol"},{"issue":"3","key":"795_CR28","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","volume":"71","author":"MA Mealy","year":"2014","unstructured":"Mealy MA, Wingerchuk DM, Palace J et al (2014) Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol 71(3):324\u2013330","journal-title":"JAMA Neurol"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13760-017-0795-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-017-0795-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-017-0795-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,21]],"date-time":"2017-08-21T10:21:35Z","timestamp":1503310895000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13760-017-0795-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,12]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["795"],"URL":"https:\/\/doi.org\/10.1007\/s13760-017-0795-6","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,12]]}}}